Magnesium deficiency increases serum fibroblast growth factor-23 levels in rats

Matsuzaki, Hiroshi; Kajita, Yasutaka; Miwa, Makoto

doi:10.1684/mrh.2013.0331

Cited by 18 publications

(29 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus chronic magnesium depletion in normal rats leads initi ally to an increase and subsequently to a decrease in serum PTH levels, 65,66 as well as to an increase in serum levels of FGF23. 67 Interestingly, dietary magnesium loading also reduced serum PTH levels in normal mice 46 and rats, but in the latter only at very high magnesium dose. 54 In rats with CKD, administration of a high dose of magnesiumcontaining phosphate binder reduced serum PTH levels and increased serum FGF23 levels.…”

Section: Systemic Effectsmentioning

confidence: 97%

Magnesium and cardiovascular complications of chronic kidney disease

Massy

Drüeke

2015

Nat Rev Nephrol

View full text Add to dashboard Cite

Cardiovascular complications are the leading cause of death in patients with chronic kidney disease (CKD). Abundant experimental evidence suggests a physiological role of magnesium in cardiovascular function, and clinical evidence suggests a role of the cation in cardiovascular disease in the general population. The role of magnesium in CKD-mineral and bone disorder, and in particular its impact on cardiovascular morbidity and mortality in patients with CKD, is however not well understood. Experimental studies have shown that magnesium inhibits vascular calcification, both by direct effects on the vessel wall and by indirect, systemic effects. Moreover, an increasing number of epidemiologic studies in patients with CKD have shown associations of serum magnesium levels with intermediate and hard outcomes, including vascular calcification, cardiovascular events and mortality. Intervention trials in these patients conducted to date have had small sample sizes and have been limited to the study of surrogate parameters, such as arterial stiffness, vascular calcification and atherosclerosis. Randomized controlled trials are clearly needed to determine the effects of magnesium supplementation on hard outcomes in patients with CKD.

show abstract

Section: Systemic Effectsmentioning

confidence: 97%

Magnesium and cardiovascular complications of chronic kidney disease

Massy

Drüeke

2015

Nat Rev Nephrol

View full text Add to dashboard Cite

show abstract

“…Magnesium furthermore appears to modify the risks associated with hyperphosphatemia in humans with CKD, as high phosphate was only associated with higher risks of death and progression to end‐stage renal disease in patients with lower serum total magnesium concentrations (tMg). Interestingly, magnesium might be involved in FGF23 regulation, because an inverse association between these two variables was observed in human CKD patients on hemodialysis, and serum FGF23 concentrations were increased in rodents fed a magnesium deficient diet . Plasma FGF23 itself is a strong predictor of survival and progression in cats with CKD …”

Section: Introductionmentioning

confidence: 99%

“…Interestingly, magnesium might be involved in FGF23 regulation, because an inverse association between these two variables was observed in human CKD patients on hemodialysis, 29 and serum FGF23 concentrations were increased in rodents fed a magnesium deficient diet. 30,31 Plasma FGF23 itself is a strong predictor of survival and progression in cats with CKD. 5 Little is known about the role of magnesium in feline CKD-MBD.…”

Section: Introductionmentioning

confidence: 99%

Prognostic importance of plasma total magnesium in a cohort of cats with azotemic chronic kidney disease

Broek

Chang

Elliott

et al. 2018

Veterinary Internal Medicne

View full text Add to dashboard Cite

BackgroundHypomagnesemia is associated with increased mortality and renal function decline in humans with chronic kidney disease (CKD). Magnesium is furthermore inversely associated with fibroblast growth factor 23 (FGF23), an important prognostic factor in CKD in cats. However, the prognostic significance of plasma magnesium in cats with CKD is unknown.ObjectivesTo explore associations of plasma total magnesium concentration (tMg) with plasma FGF23 concentration, all‐cause mortality, and disease progression in cats with azotemic CKD.AnimalsRecords of 174 client‐owned cats with IRIS stage 2‐4 CKD.MethodsCohort study. Cats with azotemic CKD were identified from the records of two London‐based first opinion practices (1999–2013). Possible associations of baseline plasma tMg with FGF23 concentration and risks of death and progression were explored using, respectively, linear, Cox, and logistic regression.ResultsPlasma tMg (reference interval, 1.73–2.57 mg/dL) was inversely associated with plasma FGF23 when controlling for plasma creatinine and phosphate concentrations (partial correlation coefficient, −0.50; P < .001). Hypomagnesemia was observed in 12% (20/174) of cats, and independently associated with increased risk of death (adjusted hazard ratio, 2.74; 95% confidence interval [CI], 1.35–5.55; P = .005). The unadjusted associations of hypermagnesemia (prevalence, 6%; 11/174 cats) with survival (hazard ratio, 2.88; 95% CI, 1.54–5.38; P = .001), and hypomagnesemia with progressive CKD (odds ratio, 17.7; 95% CI, 2.04–154; P = .009) lost significance in multivariable analysis.Conclusions and Clinical ImportanceHypomagnesemia was associated with higher plasma FGF23 concentrations and increased risk of death. Measurement of plasma tMg augments prognostic information in cats with CKD, but whether these observations are associations or causations warrants further investigation.

show abstract

“…Although the relationship between FGF23 and Mg has not been formally addressed to date, we note that dietary Mg loading has been reported to reduce serum FGF23 levels in rodent models . However, these data were obtained in mice and rats with normal kidney function.…”

Section: Discussionmentioning

confidence: 78%